PROMO.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (17 Jan 2024 @ 00:21):

Stats
今日成交量	1.12M
平均成交量	2.06M
市值	293.55M
EPS	SEK-0.0643 ( 2023-09-30 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.314
ATR14	SEK5.16 (36.49%)

音量相关性

長: -0.10 (neutral)

短: 0.27 (neutral)

Signal:(45.746) Neutral

Promore Pharma AB (publ) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Promore Pharma AB (publ) 相关性 - 货币/商品

0.30
( neutral )

0.69
( moderate )

0.07
( neutral )

0.59
( weak )

-0.02
( neutral )

-0.20
( neutral )

Promore Pharma AB (publ) 财务报表

Annual	2022
营收:	SEK99 000.00
毛利润:	SEK-15.85M (-16 005.05 %)
EPS:	SEK-0.440

FY	2022
营收:	SEK99 000.00
毛利润:	SEK-15.85M (-16 005.05 %)
EPS:	SEK-0.440

FY	2021
营收:	SEK417 000
毛利润:	SEK-14.90M (-3 571.94 %)
EPS:	SEK-0.561

FY	2020
营收:	SEK3 000.00
毛利润:	SEK-18.20M (-606 733.33 %)
EPS:	SEK-0.796

Financial Reports:

No articles found.

Promore Pharma AB (publ)

Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers. It entered into a cooperation agreement with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is headquartered in Solna, Sweden.